In a recent paper in the Journal Chung et al. report effects of the a 1 -adrenoceptor antagonist alfuzosin on sexual function when used in the open-label treatment of 148 males with voiding dysfunction. 1 Key findings of the trial include a statistically significant improvement of voiding symptoms (assessed by the International Prostate Symptom Score and free flow Q max ), as well as Male Sexual Health Questionnaire (MSHQ) and two of its three domains (satisfaction domain not significantly improved) or the International Index of Erectile Function (IIEF) when compared with baseline values. The authors conclude that alfuzosin is 'effective in improving sexual function' in the treatment of patients with benign prostatic hyperplasia.
Although the findings on voiding symptoms confirm the results from many placebo-controlled double-blind studies, 2 to the best of our knowledge there is no earlier study showing benefits of alfuzosin over placebo on sexual function under double blind conditions. 3 Double-blind comparative studies also failed to show significant benefits of alfuzosin over other a 1 -adrenoceptor antagonists with regard to sexual function. 4 Although the study by Chung et al. confirms that we do not have to expect worsening of sexual function when using this or other a 1 -adrenoceptor antagonists, 3 we feel that claims for efficacy in improving sexual function based upon open-label studies are inappropriate. The key reason for this is that overall sexual function may also exhibit considerable improvement upon placebo treatment in men with voiding dysfunction. 5 The latter study to our knowledge is the only study ever to show improvements of overall sexual function by an a 1 -adrenoceptor antagonist as compared with placebo, but it was based on a post-hoc analysis only. Another issue concerns the use of the MSHQ. Although this is a validated questionnaire providing complementary data to those captured by the IIEF, 6 in contrast to the IIEF there is little data on how this instrument behaves during placebo treatment. Therefore, we urge caution in making claims on efficacy of drugs on sexual function in the absence of controlled double-blind studies.
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